Barclays Trims Humana (NYSE:HUM) Target Price to $250.00

Humana (NYSE:HUM) had its price objective trimmed by Barclays from $364.00 to $250.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the insurance provider’s stock.

Several other research analysts also recently commented on HUM. TD Cowen downgraded Humana from a buy rating to a hold rating and reduced their price objective for the company from $402.00 to $261.00 in a research note on Monday. Oppenheimer decreased their price target on shares of Humana from $400.00 to $280.00 and set an outperform rating on the stock in a research note on Thursday, October 3rd. Leerink Partnrs cut shares of Humana from a strong-buy rating to a hold rating in a research note on Wednesday, October 2nd. Royal Bank of Canada decreased their target price on shares of Humana from $400.00 to $265.00 and set an outperform rating on the stock in a research note on Tuesday. Finally, Piper Sandler lowered Humana from an overweight rating to a neutral rating and dropped their price target for the company from $392.00 to $274.00 in a research report on Thursday, October 3rd. One analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Humana currently has a consensus rating of Hold and an average target price of $315.33.

Humana Price Performance

HUM stock traded up $1.52 during mid-day trading on Thursday, reaching $252.96. 244,125 shares of the company’s stock were exchanged, compared to its average volume of 1,792,278. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. Humana has a 12-month low of $213.31 and a 12-month high of $530.54. The stock’s 50 day moving average is $326.88 and its 200 day moving average is $340.78. The company has a market cap of $30.46 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm posted $8.94 EPS. On average, research analysts expect that Humana will post 16.06 EPS for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana’s dividend payout ratio (DPR) is currently 25.25%.

Hedge Funds Weigh In On Humana

Several large investors have recently bought and sold shares of HUM. Willner & Heller LLC boosted its position in shares of Humana by 17.2% during the 3rd quarter. Willner & Heller LLC now owns 1,562 shares of the insurance provider’s stock worth $495,000 after acquiring an additional 229 shares in the last quarter. Koshinski Asset Management Inc. lifted its stake in Humana by 32.4% during the third quarter. Koshinski Asset Management Inc. now owns 1,499 shares of the insurance provider’s stock worth $475,000 after purchasing an additional 367 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in Humana in the third quarter valued at approximately $348,000. Gateway Investment Advisers LLC raised its holdings in Humana by 6.1% during the third quarter. Gateway Investment Advisers LLC now owns 3,112 shares of the insurance provider’s stock worth $986,000 after purchasing an additional 180 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Humana by 49.6% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 4,827 shares of the insurance provider’s stock worth $1,532,000 after buying an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.